ࡱ; " !  #Root Entry  !"#$%&'()*+,-./0134568  FMicrosoft Word-Dokument MSWordDocWord.Document.89q [ZZNormal 1$*$A$/B*OJQJCJmHsHPJnHtH^JaJ_H9TT Heading 1"@& & F & F^]`$CJ5aJ\BB Heading 2@& & F & F$CJaJ"" WW8Num1z0"" WW8Num1z1"" WW8Num1z2"!" WW8Num1z3"1" WW8Num1z4"A" WW8Num1z5"Q" WW8Num1z6"a" WW8Num1z7"q" WW8Num1z8<<Default Paragraph FontFFHeading x$OJQJCJPJ^JaJ4B4 Text Bodyd  / List^J@"@Caption xx $CJ6^JaJ]&&Index $^J, ,.XX^`^`^`^`^`^`^`^`^`@, , P GTimes New Roman5Symbol3&ArialiLiberation SerifTimes New Roman3&ArialGTimes New RomanS&Liberation SansArialGMicrosoft YaHei3$ArialBh[ w' w' '' '''00B Recombinant human DecorinDr. Franz WelserEMPDr. Franz WelserEMPEMPOh+'0 PX|  Recombinant human DecorinDr. Franz WelserNormal13@2~@y 0@_/@ 0՜.+,D՜.+,M 0XCaolan80 5,, $lmb  EMP GENETECH Product Specification Sheet Recombinant Human HER2- ECD HER2/neu/ErbB-2 (human epidermal growth factor receptor 2) is a membrane glycoprotein of the ErbB family of tyrosine kinase receptors. These protein family members (ErbB1-4) serve as receptors for epidermal growth factor. ErbB2 is found on the surface of epithelial cells and is strongly overexpressed on the membrane of cancer cells especially breast cancer cells. ErbB2 has no identified ligand but rather forms heterodimers with one of the other ErbB receptors. These complexes are of high affinity to its ligands. By binding of the ligand a conformational change of the cytoplasmatic tyrosine kinase part of the ErbB2 receptor results in phosphorylation of the initial PI3K/Akt signal transduction cascade protein and effects cell proliferation. Human ErbB2 consists of 1255 amino acids (aa) with a 21 aa leader sequence, a 631 aa extracellular domain (ED), a 23 aa transmembrane region, and a 580 aa cytoplasmatic domain. The soluble ED can be shed proteolytically from the cell surface, is strongly glycosylated and of a MW of 95-105 kDa. Source: - DNA sequence for hn HER2-ED (extracellular domain) aa T23-Q646 - produced serum free in stable HEK293 cells - purified from the culture supernatant Purification: by anion exchange chromatography Formulation: lyophilized from a solution of 20 mmol Tris, 200 mmol NaCl, pH 7.4 Concentration: 1000 g/ml Purity: >95% non reduced SDS-PAGE 95-105 kDa band, partly di- and trimeric forms Identity: Immuno-Blot with specific antibody Stability: at least 12 months at  200 C, avoid repeated freeze/thaw cycles Sizes: 100 g 1000 g Cat.No: HER2-ECD100 HER2-ECD1000 Usage: laboratory reagent - not to be used as a diagnostic product or for administration to humans or used for any drug purposes References: 1. Coussens, L. et. al. (1985) Science 230:1132. 2. Yamamoto, T. et. al. (1986) Nature 319:230. 3. Kanai, Y. et. al. (1995) Biochem. Biophys. Res. Commun.208:1067. 4. Emkey, R. and C.R. Kahn (1997) J. Biol. Chem. 272:31172. 5. Schaefer, G. et. al. (1999) J. Biol. Chem. 274:859. 6. Schlessinger, J. (2000) Cell 103:211 Product Information: The protein concentration is 1000 g/ml. 1. Dissolve in 1 ml dH2O and handle the product on ice. 2 .Once dissolved aliquot and store at -20o C or below. 3. Handle the product carefully to avoid degradation. 4. Keep the working steps low to avoid protein losses. With regards, Dr. F.X. Welser TVXl n prjl "$FHJ~,.Ҿoooooooooooooo)B*phCJmH sH PJ^JaJOJQJ CJmH sH PJ^JaJOJQJ/B*phCJmH sH 5PJ^JaJ\OJQJ!B*phmH sH PJ^JOJQJ'B*phmH sH 5PJ^J\OJQJ/B*phCJ mH sH 5PJ^JaJ \OJQJ)B*phCJ mH sH PJ^JaJ OJQJ+.0(*Pfh024JLl|  &6u&CJmH sH 5PJ^JaJ\OJQJ CJmH sH PJ^JaJOJQJ&CJmH sH 6PJ^JaJ]OJQJ CJmH sH PJ^JaJOJQJ&CJmH sH 5PJ^JaJ\OJQJ,B*phH*CJmH sH PJ^JaJOJQJ)B*phCJmH sH PJ^JaJOJQJ*  ,<hnxzNPR02  .0246TVX®®®®œ#H*CJmH sH PJ^JaJOJQJ&CJmH sH 5PJ^JaJ\OJQJ CJmH sH PJ^JaJOJQJCJ6PJ^JaJ]OJQJCJ5PJ^JaJ\OJQJCJPJ^JaJOJQJ.VXn r  & F1$^]`~  & F$a$1$ 1$^]`  & F1$^]`  & F1$^]`  & F1$^]`  & F1$^]`  & F1$^]`  & F1$^ ]`l"$HJ.0  & F1$^]`~ & F1$  & F1$^]`~  & F1$^]`~  & F1$^]`~  & F1$^]`~  & F1$^L]`  & F1$^]`~ & F$a$1$^]`~*h24L  z 1$^]`~  & F1$^]`~  & F1$^]`~  & F1$^]`~  & F1$^]`~ & F1$ & F1$  & F1$^]`~PR2 0246VXdd3<0. A!Q"n#n$n2P1h0p3P(20\Root Entry F@CompObjjOle 1Table SummaryInformation(2WordDocument 5,DocumentSummaryInformation87t